
Paratek Pharmaceuticals PRTK
Quarterly report 2023-Q2
added 08-03-2023
Paratek Pharmaceuticals Total Current Liabilities 2011-2026 | PRTK
Annual Total Current Liabilities Paratek Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.4 M | 31.3 M | 24 M | 24.2 M | 17.7 M | 16.8 M | 20.4 M | 20.5 M | 3.74 M | 34.8 M | 2.66 M | 3.34 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.4 M | 2.66 M | 19.7 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 19.14 | 0.74 % | $ 895 M | ||
|
Anika Therapeutics
ANIK
|
31.1 M | $ 14.74 | -0.2 % | $ 216 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.63 | 3.5 % | $ 434 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
47.5 M | - | - | $ 269 M | ||
|
Esperion Therapeutics
ESPR
|
301 M | $ 3.13 | -0.48 % | $ 651 M | ||
|
Exelixis
EXEL
|
406 M | $ 49.35 | 2.47 % | $ 13.4 B | ||
|
Fortress Biotech
FBIO
|
49.7 M | $ 2.36 | -1.26 % | $ 65.8 M | ||
|
Forte Biosciences
FBRX
|
20.8 M | $ 24.9 | 3.65 % | $ 322 M | ||
|
AbbVie
ABBV
|
43.3 B | $ 203.32 | 0.97 % | $ 360 B | ||
|
Gilead Sciences
GILD
|
11.8 B | $ 133.2 | 1.42 % | $ 166 B | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Compugen Ltd.
CGEN
|
22.6 M | $ 2.82 | -2.76 % | $ 263 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
9.02 M | $ 0.77 | 0.16 % | $ 35.2 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
395 M | $ 22.41 | 0.04 % | $ 3.71 B | ||
|
Genprex
GNPX
|
2.17 M | $ 0.85 | -1.99 % | $ 793 K | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.46 | -1.98 % | $ 5.7 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 21.09 | -0.4 % | $ 2.68 B | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
6.18 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M |